Research information only. PrecisePep is an educational library. It is not medical advice and is not intended to assist, encourage or enable self-administration. The compounds documented here are research chemicals — most are not approved for human use. Read the full disclaimer.
PrecisePep/Peptide Library/Dulaglutide
Metabolic & Adipose Regulation
Trulicity® · LY2189265
A GLP-1 agonist fused to an antibody fragment rather than acylated — the one whose cardiovascular trial was run largely in people who had not yet had an event, and the one with the strongest kidney signal.
Dulaglutide solves the half-life problem differently from every other agent in this library. Semaglutide, liraglutide and tirzepatide all attach a fatty-acid chain to bind albumin. Dulaglutide instead fuses two GLP-1 analogue molecules to a human IgG4 Fc fragment — borrowing antibody recycling machinery to achieve a five-day half-life. The result is a much larger molecule, around 60 kDa against roughly 4 kDa for the acylated peptides.
Its distinguishing trial is REWIND, which differed from the other cardiovascular outcome trials in an important way: most participants had cardiovascular risk factors rather than established disease. It reported reduced major adverse cardiovascular events in that largely-primary-prevention population, which is a harder result to obtain and arguably a more broadly applicable one.[1] An exploratory renal analysis reported reduced kidney outcomes.[2]
On potency it sits below semaglutide and well below tirzepatide for both HbA1c and weight. It is not approved for obesity at all — it is a diabetes drug with a cardiovascular indication, and that narrower positioning is why it appears far less in weight-loss discussion.
A 60 kDa protein is not a peptide in the sense the rest of this library uses the word. It is considerably more fragile, more prone to aggregation, and more difficult to characterise or synthesise than an acylated 31-residue peptide. That makes credible grey-market dulaglutide substantially less plausible than grey-market semaglutide — which is worth knowing before buying something labelled as it.
GLP-1 receptor agonism. The standard class mechanism — glucose-dependent insulinotropic effect, glucagon suppression, slowed gastric emptying, central appetite suppression.
Fc fusion for half-life extension. The IgG4 Fc fragment engages the neonatal Fc receptor recycling pathway that keeps antibodies in circulation for weeks, extending the GLP-1 analogue half-life to about five days. A structurally different solution to the same problem acylation solves.
Size consequences. The large molecule distributes differently and is cleared by proteolytic degradation rather than renal filtration. It also raises immunogenicity considerations that small acylated peptides largely avoid, though anti-drug antibody rates in trials were low.
Renal effects. Proposed to reduce glomerular hyperfiltration and blunt intrarenal inflammatory signalling — the mechanistic account offered for the REWIND renal findings, and consistent with the broader class pattern seen most clearly with semaglutide in FLOW.
Effects that have been reported. A study-tier entry means a result was published — not that the effect is established, reproducible, or transferable from a rodent to a person.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Randomised trial in over 9,900 adults with type 2 diabetes, the majority of whom had cardiovascular risk factors rather than established disease. Reported reduced major adverse cardiovascular events over a median follow-up beyond five years — a broader population than most CVOTs in this class enrolled.
A pre-specified exploratory analysis reported reduced composite renal outcomes, driven substantially by new macroalbuminuria. Exploratory rather than a primary endpoint, and consistent with the class pattern.
A multi-trial phase 3 programme establishing glycaemic efficacy against metformin, sitagliptin, exenatide, insulin glargine and liraglutide comparators.
Weight reduction is real but well below semaglutide and tirzepatide. Dulaglutide holds no obesity indication, and that is a reflection of the effect size rather than an oversight.
The licensed product ships as a single-dose pen with a hidden, pre-attached needle — a genuine adherence advantage that trials in the AWARD programme examined directly.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
The renal analysis was exploratory. Semaglutide subsequently produced a dedicated renal outcomes trial in FLOW, which is stronger evidence for a class effect than dulaglutide has for itself.
REWIND enrolled a lower-risk population than most CVOTs, so its result arguably generalises more widely. A reasonable inference and not something the trial set out to test.
Anti-drug antibody rates were low in trials. Long-horizon immunogenicity in unmonitored use is uncharacterised.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Frequently reported as gentler than semaglutide on gastrointestinal effects, consistent with the smaller weight effect.
The dominant complaint in community discussion, and entirely consistent with the trial data — it is not an obesity drug.
The Fc-fusion structure makes credible unlicensed synthesis far harder than for acylated peptides. Anything sold as research-grade dulaglutide deserves particular scepticism.
The hidden-needle single-dose device is consistently mentioned as easier than pens requiring needle attachment and dose dialling.
Adverse effects, contraindications and unknowns. The grey-market tier is where under-reporting is worst: uncontrolled use produces no systematic safety surveillance at all, so absence of a reported harm is not evidence of safety.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Nausea, diarrhoea and vomiting dominate, dose-dependent and concentrated early, at rates generally below semaglutide.
From rodent findings. Contraindicated in personal or family history of medullary thyroid carcinoma or MEN2.
Labelled class warnings.
Glucose-dependence limits intrinsic risk; concurrent insulin or sulfonylurea therapy removes that protection and requires dose reduction of those agents.
A class consideration in patients with existing retinopathy.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Trial antibody rates were low, but a fusion protein carries a different immunogenicity profile from a small acylated peptide, and long-horizon unmonitored use has no characterisation.
A 60 kDa fusion protein is materially harder to synthesise and verify than an acylated peptide. Standard purity assays used in this market are poorly suited to confirming it.
Delayed gastric emptying alters absorption of a narrow-therapeutic-index, fasting-dependent drug.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
The main complaints, generally milder than with semaglutide.
Reported at typical rates.
Occasionally reported, as across the class.
Figures below are documented, not recommended. Study ranges come from published protocols in the stated model; grey-market ranges are what the research community reports using and carry no safety validation of any kind.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Start at 0.75 mg once weekly, increase to 1.5 mg, then in 1.5 mg increments after at least four weeks at each dose, to a maximum of 4.5 mg weekly.
The 3.0 and 4.5 mg doses were added on the basis of trial work demonstrating additional glycaemic and weight benefit over 1.5 mg.
| Step | Dose | Minimum interval | Note |
|---|---|---|---|
| Start | 0.75 mg weekly | 4 weeks | Therapeutic, unlike some class starting doses |
| Standard | 1.5 mg weekly | 4 weeks | The most-used maintenance dose |
| Escalated | 3.0 mg weekly | 4 weeks | Added following AWARD-11 |
| Maximum | 4.5 mg weekly | — | Labelled ceiling |
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Adverse events are dose-ordered, as across the class.
The REWIND population and the modest weight effect together define where this agent fits. Clinical reasoning rather than a trial finding.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
The common range, matching the labelled starting and standard doses.
The higher labelled doses, used where glycaemic control is the objective.
Combination effects. Almost no peptide combination has been studied as a combination in humans; stack logic is overwhelmingly mechanistic inference and community practice. Each linked compound has its own page.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
The AWARD programme evaluated dulaglutide with metformin, sulfonylureas, thiazolidinediones and insulin — genuine combination trial data rather than inference.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Same receptor, additive adverse effects, no additional mechanism.
Requires dose reduction of the concurrent agent — the most likely route to harm in a diabetes population.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
The standard clinical pairing.
Whole schedules — dosing, titration, cycle length, and off-time — as documented in trials, as proposed from mechanism, and as circulated in the research community. Reproduced for study and comparison only.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
The endpoint the drug is titrated against clinically.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Community practice generally follows the label here, which is unusual and probably reflects that most users obtained it on prescription.
Dulaglutide is the agent in this class most people skip over, and its distinguishing features are both worth knowing: the population its outcome trial enrolled, and the fact that its structure makes credible grey-market supply implausible.
Approved for type 2 diabetes and for cardiovascular risk reduction in that population. It holds no obesity indication, which reflects the size of the weight effect rather than a gap in the licence.
Pathophysiology
Nicotine dependence is maintained by mesolimbic dopamine signalling. Quitting also produces a documented average weight gain of several kilograms, driven by restored appetite and slowed metabolic rate — and fear of that gain is a measured barrier to attempting cessation and a measured cause of relapse, particularly in women.
Mechanistic rationale
A single-centre randomised, double-blind, placebo-controlled trial gave dulaglutide 0.75 mg for one week then 1.5 mg for twelve, alongside varenicline and behavioural counselling. Abstinence was 63% on dulaglutide against 65% on placebo — no difference. Weight, however, separated sharply: −4.6 kg on dulaglutide against +0.5 kg on placebo. A twelve-month follow-up was published subsequently.
Community reports
Read the null result carefully rather than as a failure. It did not help people quit. It did solve the specific problem that stops many people trying — and it did so on top of varenicline, not instead of it. Nobody has tested a GLP-1 alone against placebo for abstinence.
Components carrying the argument: GLP-1 receptor — appetite, not abstinence
Pathophysiology
Most cardiovascular outcome trials enrol people who have already had an event, where absolute risk is high and benefit is easiest to demonstrate.
Mechanistic rationale
REWIND was different: the majority of its 9,900 participants had cardiovascular risk factors rather than established disease, and it still reported reduced major adverse cardiovascular events over a median beyond five years. A result in a lower-risk population is harder to obtain and arguably generalises more widely, which is this agent’s real distinguishing feature.
Community reports
Rarely the reason people choose it, because weight loss dominates the conversation.
Components carrying the argument: GLP-1 receptor agonism
Pathophysiology
Diabetic kidney disease progresses through albuminuria to declining filtration, and is a leading cause of end-stage renal disease.
Mechanistic rationale
A pre-specified exploratory REWIND analysis reported reduced composite renal outcomes, driven substantially by new macroalbuminuria. Exploratory rather than a primary endpoint — and semaglutide subsequently ran FLOW, a dedicated renal outcomes trial, which is stronger evidence for a class effect than dulaglutide has for itself.
Community reports
Cited for kidney benefit without the exploratory caveat.
Components carrying the argument: Reduced glomerular hyperfiltration, class effect
Pathophysiology
Not a condition. A structural fact with a practical consequence.
Mechanistic rationale
Semaglutide, liraglutide and tirzepatide are acylated peptides of roughly 4 kDa. Dulaglutide is a GLP-1 analogue fused to an IgG4 Fc fragment — around 60 kDa, a fusion protein rather than a peptide. It is far harder to synthesise, far harder to verify, and standard purity assays used in this market are poorly suited to confirming it. Anything sold as research-grade dulaglutide warrants particular scepticism about what is actually in the vial.
Community reports
Rare in grey-market channels, which is consistent with the difficulty.
Components carrying the argument: Fc fusion — size and complexity
Pathophysiology
PCOS, thyroid interaction, fatty liver and the fertility consequence are class-wide.
Mechanistic rationale
These are set out in full on the semaglutide and liraglutide pages, including the delayed gastric emptying effect on levothyroxine absorption and the pregnancy contraindication. Dulaglutide shares them, with a smaller weight effect.
Community reports
Consistently described as gentler on gastrointestinal effects than semaglutide, which is consistent with the smaller weight effect.
Components carrying the argument: Class effects
| Question | Position |
|---|---|
| Approved for | Type 2 diabetes; cardiovascular risk reduction |
| Obesity indication | None — the weight effect is modest |
| REWIND population | Largely primary prevention — a harder test |
| Renal data | Exploratory; FLOW with semaglutide is stronger |
| Molecular size | ~60 kDa Fc fusion — not a peptide in the usual sense |
| Grey-market plausibility | Low — be sceptical of what is in the vial |
For type 2 diabetes and cardiovascular risk: metformin, SGLT2 inhibitors, GLP-1 agonists with outcome data, blood-pressure control, statins and smoking cessation. For kidney disease: ACE inhibitors or ARBs, SGLT2 inhibitors, finerenone, and avoidance of nephrotoxins including NSAIDs.
Physical-chemistry reference for laboratory handling of the lyophilised material. Reproduced so that stability and concentration mathematics can be studied — see the calculator for the arithmetic and the reconstitution guide for sterile technique.
The licensed product is a single-dose pre-filled pen requiring no reconstitution or dose dialling. Credible research-grade dulaglutide is uncommon; the Fc-fusion structure is substantially harder to synthesise and verify than the acylated peptides that dominate this market.
Refrigerated 2–8 °C, with a defined room-temperature in-use period. Protect from light. Do not freeze — a fusion protein is less tolerant of freeze–thaw than a small peptide.
Licensed: 0.75, 1.5, 3.0 and 4.5 mg single-dose pens.
A large fusion protein is more prone to aggregation and denaturation than an acylated peptide, and standard purity assays used in the grey market are poorly suited to confirming its identity.
Regulatory status changes and differs by country. This is a summary for orientation, not legal advice — check your own jurisdiction.
Also approved in children. Safety and effectiveness as an adjunct to diet and exercise for glycaemic control were established in paediatric patients aged 10 and over with type 2 diabetes, supported by a 26-week randomised placebo-controlled trial in 154 children and adolescents.
Approved. Licensed as Trulicity for type 2 diabetes and for cardiovascular risk reduction in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. Prescription medicine with a boxed warning.
Unlike most of this class, it holds no obesity indication — which is a statement about the size of the weight effect rather than a gap in the licence.
Regulatory and trial claims re-checked against primary sources on 16 August 2026. Checked: current label including the paediatric indication from age 10; the dulaglutide smoking cessation RCT and its 12-month follow-up. Approvals, trial readouts and compounding decisions move faster than anything else on this page — a date here means someone looked, not that nothing has changed since.
Metabolic modulators and peptide hormones are addressed under the WADA Prohibited List. Verify against the current list.
Links resolve to PubMed records, trial registries, publisher pages or primary documents. Where a body of work rather than a single paper is cited, the link opens a PubMed query so the full result set — including newer papers than this page — can be reviewed. Verify every claim against the primary source before relying on it.
For educational and research reference only. Nothing on this site is medical advice, a recommendation, or an instruction to administer any substance to a human being. Every figure on this page is a record of what has been reported, not a recommendation. Full disclaimer.
